APA (7th ed.) Citation

FK, D., AF, C., Z, E., N, E., SG, S., BK, P., . . . Ç, K. (2025). A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats. Journal of diabetes and metabolic disorders, 24(2), 288. https://doi.org/10.1007/s40200-025-01723-4

Chicago Style (17th ed.) Citation

FK, Dagistanli, Ceylan AF, Elmazoglu Z, Efendiyeva N, Sarıbaş SG, Pilafi BK, Stefek M, Ulusu NN, and Karasu Ç. "A Comparative Study to Assess Two Doses of a Novel Aldose Reductase Inhibitor (ARI)/Antioxidant Drug Candidate Cemtirestat, the Current ARI Drug Epalrestat, and the Antioxidant Stobadine on Fructose- and Streptozotocin-Induced Hepatic and Pancreatic Stress Responses in Rats." Journal of Diabetes and Metabolic Disorders 24, no. 2 (2025): 288. https://doi.org/10.1007/s40200-025-01723-4.

MLA (9th ed.) Citation

FK, Dagistanli, et al. "A Comparative Study to Assess Two Doses of a Novel Aldose Reductase Inhibitor (ARI)/Antioxidant Drug Candidate Cemtirestat, the Current ARI Drug Epalrestat, and the Antioxidant Stobadine on Fructose- and Streptozotocin-Induced Hepatic and Pancreatic Stress Responses in Rats." Journal of Diabetes and Metabolic Disorders, vol. 24, no. 2, 2025, p. 288, https://doi.org/10.1007/s40200-025-01723-4.